Mostrar el registro sencillo del ítem
dc.contributor.author | Loras, Alba | es_ES |
dc.contributor.author | Suárez-Cabrera, Cristian | es_ES |
dc.contributor.author | Martínez-Bisbal, M.Carmen | es_ES |
dc.contributor.author | Quintás, Guillermo | es_ES |
dc.contributor.author | Paramio, Jesús M. | es_ES |
dc.contributor.author | Martínez-Máñez, Ramón | es_ES |
dc.contributor.author | Gil Grau, Salvador | es_ES |
dc.contributor.author | Ruiz-Cerdá, José Luis | es_ES |
dc.date.accessioned | 2023-05-16T18:01:10Z | |
dc.date.available | 2023-05-16T18:01:10Z | |
dc.date.issued | 2019-05 | es_ES |
dc.identifier.uri | http://hdl.handle.net/10251/193434 | |
dc.description.abstract | [EN] Metabolism reprogramming is considered a hallmark of cancer. The study of bladder cancer (BC) metabolism could be the key to developing new strategies for diagnosis and therapy. This work aimed to identify tissue and urinary metabolic signatures as biomarkers of BC and get further insight into BC tumor biology through the study of gene-metabolite networks and the integration of metabolomics and transcriptomics data. BC and control tissue samples (n = 44) from the same patients were analyzed by High-Resolution Magic Angle Spinning Nuclear Magnetic Resonance and microarrays techniques. Besides, urinary profiling study (n = 35) was performed in the same patients to identify a metabolomic profile, linked with BC tissue hallmarks, as a potential non-invasive approach for BC diagnosis. The metabolic profile allowed for the classification of BC tissue samples with a sensitivity and specificity of 100%. The most discriminant metabolites for BC tissue samples reflected alterations in amino acids, glutathione, and taurine metabolic pathways. Transcriptomic data supported metabolomic results and revealed a predominant downregulation of metabolic genes belonging to phosphorylative oxidation, tricarboxylic acid cycle, and amino acid metabolism. The urinary profiling study showed a relation with taurine and other amino acids perturbed pathways observed in BC tissue samples, and classified BC from non-tumor urine samples with good sensitivities (91%) and specificities (77%). This urinary profile could be used as a non-invasive tool for BC diagnosis and follow-up. | es_ES |
dc.description.sponsorship | This research was funded by FEDER cofounded MINECO grant SAF2015-66015-R, MAT2015-64139-C4-1-R, MAT2015-64139-C4-3-R, ISCIII-RETICRD12/0036/0009, PIE 15/00076, CB/16/00228, CTQ2016-79561-P; and the PROMETEO II/2014/047 and PROMETEO 2018/24 projects. | es_ES |
dc.language | Inglés | es_ES |
dc.publisher | MDPI AG | es_ES |
dc.relation.ispartof | Cancers | es_ES |
dc.rights | Reconocimiento (by) | es_ES |
dc.subject | Cancer biomarkers | es_ES |
dc.subject | Bladder cancer | es_ES |
dc.subject | Metabolomics | es_ES |
dc.subject | Transcriptomics | es_ES |
dc.subject | Metabolic pathways | es_ES |
dc.subject | Tumor metabolome | es_ES |
dc.subject | Cancer metabolic reprogramming | es_ES |
dc.subject.classification | QUIMICA INORGANICA | es_ES |
dc.title | Integrative Metabolomic and Transcriptomic Analysis for the Study of Bladder Cancer | es_ES |
dc.type | Artículo | es_ES |
dc.identifier.doi | 10.3390/cancers11050686 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/MINECO//MAT2015-64139-C4-1-R/ES/NANOMATERIALES INTELIGENTES, SONDAS Y DISPOSITIVOS PARA EL DESARROLLO INTEGRADO DE NUEVAS HERRAMIENTAS APLICADAS AL CAMPO BIOMEDICO/ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/GENERALITAT VALENCIANA//PROMETEO%2F2018%2F024//SISTEMAS AVANZADOS DE LIBERACION CONTROLADA/ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/MINECO//MAT2015-64139-C4-3-R/ES/DESARROLLO DE EQUIPOS Y DISPOSITIVOS ELECTRONICOS COMO SISTEMA DE DETECCION Y ACTUACION BASADOS EN NUEVAS TECNOLOGIAS ELECTRONICAS. APLICACION AL AREA BIOMEDICA/ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/GVA//PROMETEOII%2F2014%2F047//Nuevas aproximaciones para el diseño de materiales de liberación controlada y la detección de compuestos peligrosos/ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/MINECO//PIE15%2F00076/ES/Discovery, Validation and Implementation of Biomarkers for Precision Oncloogy/ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII//RETICRD12%2F0036%2F0009/ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/MINECO//SAF2015-66015-R/ES/UNDERSTANDING BLADDER CANCER THROUGH GENETICALLY ENGINEERED MOUSE MODELS OF PRECLINICAL APPLICATION/ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/MINECO//CB%2F16%2F00228/ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/MINECO//CTQ2016-79561-P/ | es_ES |
dc.rights.accessRights | Abierto | es_ES |
dc.contributor.affiliation | Universitat Politècnica de València. Escuela Técnica Superior de Ingenieros Industriales - Escola Tècnica Superior d'Enginyers Industrials | es_ES |
dc.description.bibliographicCitation | Loras, A.; Suárez-Cabrera, C.; Martínez-Bisbal, M.; Quintás, G.; Paramio, JM.; Martínez-Máñez, R.; Gil Grau, S.... (2019). Integrative Metabolomic and Transcriptomic Analysis for the Study of Bladder Cancer. Cancers. 11(5):1-19. https://doi.org/10.3390/cancers11050686 | es_ES |
dc.description.accrualMethod | S | es_ES |
dc.relation.publisherversion | https://doi.org/10.3390/cancers11050686 | es_ES |
dc.description.upvformatpinicio | 1 | es_ES |
dc.description.upvformatpfin | 19 | es_ES |
dc.type.version | info:eu-repo/semantics/publishedVersion | es_ES |
dc.description.volume | 11 | es_ES |
dc.description.issue | 5 | es_ES |
dc.identifier.eissn | 2072-6694 | es_ES |
dc.identifier.pmid | 31100982 | es_ES |
dc.identifier.pmcid | PMC6562847 | es_ES |
dc.relation.pasarela | S\389761 | es_ES |
dc.contributor.funder | GENERALITAT VALENCIANA | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.contributor.funder | MINISTERIO DE ECONOMIA Y EMPRESA | es_ES |
dc.contributor.funder | European Regional Development Fund | es_ES |
dc.contributor.funder | Ministerio de Economía y Competitividad | es_ES |